Trial Profile
10-day Decitabine Versus Conventional Chemotherapy ("3+7") Followed by Allografting in AML Patients greater than or equal to 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Cytarabine; Daunorubicin; Etoposide; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 12 Dec 2023 Results assessing decitabine treatment in Measurable Residual Disease-negativity, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 14 Feb 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2023.
- 13 Dec 2022 Results reporting health-related quality of life secondary outcome of this trial presented at the 64th American Society of Hematology Annual Meeting and Exposition